OBJECT DRUGS
Kinase Inhibitors:
- Axitinib (Inlyta)
- Bosutinib (Bosulif)
- Cabozantinib (Cometriq)
- Ceritinib (Zykadia)
- Cobimetinib (Cotellic)
- Crizotinib (Xalkori)
- Dabrafenib (Tafinlar)
- Dasatinib (Sprycel)
- Erlotinib (Tarceva)
- Gefitinib (Iressa)
- Ibrutinib (Imbruvica)
- Idelalisib (Zydelig)
- Imatinib (Gleevec)
- Lapatinib (Tykerb)
- Nilotinib (Tasigna)
- Osimertinib (Tagrisso)
- Pazopanib (Votrient)
- Regorafenib (Stivarga)
- Ruxolitinib (Jakafi)
- Sorafenib (Nexavar)
- Sunitinib (Sutent)
- Tofacitinib (Xeljanz)
- Vandetanib (Caprelsa)
- Vemurafenib (Zelboraf)
PRECIPITANT DRUGS
Enzyme Inducers:
- Barbiturates
- Bosentan (Tracleer)
- Carbamazepine (Tegretol, etc.)
- Dabrafenib (Tafinlar)
- Efavirenz (Sustiva)
- Etravirine (Intelence)
- Lumacaftor (Orkambi)
- Nevirapine (Viramune, etc.)
- Oxcarbazepine (Trileptal, etc.)
- Phenytoin (Dilantin, etc.)
- Primidone (Mysoline)
- Rifabutin (Mycobutin)
- Rifampin (Rifadin, etc.)
- Rifapentine (Priftin)
- St. John's wort
Comment:
Although data are limited, these enzyme inducers may decrease the plasma levels of kinase inhibitors. Reduction in the expected antineoplastic activity or resistance may occur. Lapatinib is metabolized into a hepatotoxic metabolite; inducers may increase the risk of hepatotoxicity.
Class 3: Assess Risk & Take Action if Necessary
- Monitor: Monitor for altered antineoplastic response if the CYP3A4 inducer is initiated, discontinued, or changed in dosage.